Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | Signal Management Processes Following EMA GuidelinesPharmacovigilance, Drug Safety and Risk Management 2015 - A CPD Certified Conference
By: SMi Group “I have been part of implementing a new signal management process in Novo Nordisk according to EMA regulations and guidelines. The perspective I will bring is practical experience working with the new regulations. Hopefully I should be able to provide attendees with an overview of how patient safety is thought into the drug development cycle as well as the post-marketing phase at Novo Nordisk. I will also present some of the challenges we face" - Dr Kashif Sheikh, Senior Safety Surveillance Advisor, Novo Nordisk Signal detection analysis will be a major focus of the CPD certified conference and will also include addresses from Quintiles, Mundipharma and Drug Research Safety Unit. Plus, following on from a recent PRAC meeting, delegates will also hear a keynote from PRAC member, Doris Irene Stenver, who will be providing the latest PRAC updates in an address on greater integration and internationalisation. A snap shot of those who have already confirmed attendance include: Bluefish pharmaceuticals, Daiichi Sankyo UK Ltd, Danish Medicines Agency, Drug Safety Research Unit, EudraVigilance Consultants, MedDRA Maintenance and Support Services Organisation (MSSO), NDA Regulatory Science, Novartis International AG, Novonordisk, Pfizer Ltd, pharsafer associates, ProductLife, Quintiles, Roche Products, Royal College of Physicians London, Solvay Pharmaceuticals, Takeda Chemical Industries, TEVA Pharmaceuticals, Vifor Pharma. For further information or to register, please visit http://www.smi- Pharmacovigilance, Drug Safety & Risk Management 11-12 May 2015 Holiday Inn Regents Park Hotel, London UK www.pharmacovigilance- ---END--- About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to- End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|